Glaucoma Research Unit, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Department of Ophthalmology, University of California.
J Glaucoma. 2020 Jul;29(7):542-549. doi: 10.1097/IJG.0000000000001542.
The study compared 1-year effectiveness of single trabecular microbypass stent (iStent) implantation with phacoemulsification among glaucoma severities in primary open-angle glaucoma. The study found that mild glaucoma had greater success rate and lower number of medications compared with moderate and severe glaucoma.
To evaluate the effectiveness of iStent implantation in combination with cataract surgery in moderate to severe glaucoma compared with mild glaucoma.
Medical charts of primary open-angle glaucoma subjects undergoing 1 iStent implantation were retrospectively reviewed. Glaucoma was classified on the basis of mean deviation (MD) of the preoperative standard automated perimetry into mild (MD>-6 dB), moderate (MD -6 to -12 dB), and severe (MD<-12 dB). Mixed effect regression models were performed to determine the effect of iStent at 1 year. The outcomes included as follows: (1) intraocular pressure (IOP) and the number of medications, (2) eyes with IOP ≤ severity-based target (18 mm Hg for mild, 15 mm Hg for moderate, 12 mm Hg for severe) (2A) without medication, and (2B) with medication reduction.
In total, 104 eyes from 89 subjects were analyzed. Cataract combined with iStent surgery significantly lowered the number of medications in all groups and significantly decreased IOP in moderate and severe glaucoma (P<0.05). There was significantly higher number of medications in moderate (β: 0.58, P=0.002) and severe (β: 1.20, P<0.001) compared with mild glaucoma. Eyes with moderate glaucoma had significantly lower rate of success (criterion 2A) compared with mild glaucoma [odds ratio (OR): 0.008, P=0.047]. Eyes with moderate and severe glaucoma had significantly lower rates of success (criterion 2B) (moderate vs. mild OR: 0.002, P=0.028; severe vs. mild OR: 0.026, P=0.026).
Combined phacoemulsification with iStent seems to have a better IOP-lowering and medication-lowering effect in mild glaucoma cases versus those with moderate and severe glaucoma. This difference was found in real-world data over one-year follow-up period. Long-term studies with defined IOP goals and medication removal protocols are warranted.
本研究比较了原发性开角型青光眼不同严重程度下小梁微管旁路支架(iStent)植入联合白内障超声乳化术与单纯白内障超声乳化术的 1 年疗效。研究发现,与中重度青光眼相比,轻度青光眼的成功率更高,用药量更少。
评估 iStent 植入联合白内障超声乳化术治疗中重度青光眼的疗效。
回顾性分析行 1 次 iStent 植入的原发性开角型青光眼患者的病历。根据术前标准自动视野计的平均偏差(MD)将青光眼分为轻度(MD>-6dB)、中度(MD-6 至-12dB)和重度(MD<-12dB)。采用混合效应回归模型确定 iStent 在 1 年后的效果。结果包括:(1)眼压(IOP)和用药数量;(2)IOP≤基于严重程度的目标值(轻度 18mmHg,中度 15mmHg,重度 12mmHg)的眼数(2A)不使用药物和(2B)药物减少。
共分析了 89 例患者的 104 只眼。白内障联合 iStent 手术可显著降低所有组别的用药数量,并显著降低中重度青光眼的 IOP(P<0.05)。与轻度青光眼相比,中重度青光眼的用药数量明显增加(β:0.58,P=0.002)和(β:1.20,P<0.001)。中度青光眼的成功率(标准 2A)明显低于轻度青光眼[优势比(OR):0.008,P=0.047]。中重度青光眼的成功率(标准 2B)明显低于轻度青光眼(中度 vs 轻度 OR:0.002,P=0.028;重度 vs 轻度 OR:0.026,P=0.026)。
与中重度青光眼相比,在轻度青光眼病例中,白内障超声乳化联合 iStent 似乎具有更好的降低眼压和减少用药的效果。在为期一年的随访中,在真实世界数据中发现了这一差异。需要进行长期研究,以明确眼压目标和药物去除方案。